What Aquestive Therapeutics’ Anaphylm CRL reveals about human factors scrutiny in emergency-use drug approvals
FDA halts Anaphylm over human factors risks. Find out what this means for non-injectable epinephrine and future anaphylaxis treatments.
Can ALK-Abelló’s EURneffy launch shift real-world adoption of non-injectable adrenaline in EU schools?
EMA backs EURneffy 1 mg for pediatric anaphylaxis in EU. Discover how needle-free adrenaline could reshape allergy emergency response today.
Frontage expands US–China clinical footprint to meet demand for early phase integration
Frontage Laboratories expands US and China early phase clinical sites with radiolabel, BE, and oncology focus. Find out what this means for CRDMOs in 2026.
Tenacia’s ZTALMY launch shows new blueprint for orphan neurology drugs in China
ZTALMY gains commercial launch in China for CDKL5 seizures. Find out what this means for rare disease drug access and neurology strategy.
Lilly’s $3.5bn Pennsylvania site will anchor U.S. manufacturing for next-gen injectables including retatrutide
Eli Lilly and Company has announced a $3.5 billion investment to build a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania. The site will focus on producing next-generation weight-loss medicines, including the investigational triple hormone receptor agonist retatrutide. Set to become operational by 2031, this is Lilly’s fourth new U.S. manufacturing site […]
What ALX Oncology’s new CD47 findings suggest about biomarker-driven immuno-oncology strategies
Discover how ALX Oncology’s CD47 biomarker data could reshape immuno-oncology strategies and what risks still stand for evorpacept.
What Vetter Pharma’s Saarland project reveals about long-cycle CDMO investment strategies
Vetter Pharma commits €480M to build a new commercial injectable manufacturing site in Saarland, Germany; explore industry impact and CDMO capacity shifts.
What Quince’s failed NEAT trial reveals about rare pediatric trial design risks
Quince Therapeutics ends clinical development of eDSP for A-T after Phase 3 failure. Find out what this means for its platform and future strategy.
Is Biocodex’s Fullify the first probiotic to challenge GLP-1 drugs in the consumer weight-loss space?
Biocodex launches Fullify, a gut-brain axis probiotic for appetite control. Find out what this means for weight loss, microbiome science, and the supplement industry.
How Galderma’s Wake Up To Restylane campaign reflects evolving aesthetics patient preferences
Explore how Galderma’s Wake Up To Restylane strategy and new IMCAS data could reshape aesthetic practice and hyaluronic acid filler adoption.